Marisa Wexler, MS,  senior science writer—

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

CF Trust, CF Foundation Launch Gene-editing Project

The U.K. Cystic Fibrosis Trust, in collaboration with the U.S. Cystic Fibrosis Foundation, is launching a new strategic research center (SRC) dedicated to studying gene editing as a potential treatment strategy for cystic fibrosis (CF). “Making gene editing a reality for people with CF will take the…

Change in CF Treatment Patterns in UK Seen With Use of Kalydeco

Since the introduction of Kalydeco (ivacaftor) in the U.K., marked changes in treatment patterns for cystic fibrosis (CF) patients using the medication have become noticeable over time, a study reported. Specifically, people treated with Kalydeco were less likely to continue with other treatments, such as inhaled antibiotics or…

Epicore Launches Wearable Patch to Analyze Sweat of CF Patients

Epicore Biosystems has launched in the U.S. a wearable patch allowing it to collect and analyze sweat for biomarker research, the company announced. Called the Discovery Patch Sweat Collection System, it may be useful in monitoring changes in sweat chloride in people with cystic fibrosis (CF), among other applications.

Phase 1 Study of KB407 Green-lighted in Australia

A research ethics committee in Australia has given Krystal Biotech the go-ahead to start a Phase 1 clinical study of KB407, the company’s investigational inhaled gene therapy for cystic fibrosis (CF). Enrollment for the trial is expected to start soon, according to Krystal, following approval from the…

Trikafta Now Covered in 2 More Canadian Provinces

The publicly funded drug access programs in the Canadian provinces of Alberta and Saskatchewan are now covering the triple-combination therapy Trikafta for eligible patients with cystic fibrosis (CF). These provinces join Ontario as the first to confirm coverage of Trikafta in Canada. “It’s a relief to know that…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.